SV2A: Synaptic vesicle glycoprotein 2A
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission.
- Drugs that act on it: 3
- With a US drug page: 2
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Brivaracetam | Approved | Synaptic vesicle glycoprotein 2A modulator | Modulator | — |
| Levetiracetam | Approved | Synaptic vesicle glycoprotein 2A modulator | Modulator | — |
| Seletracetam | — | Synaptic vesicle glycoprotein 2A modulator | Modulator | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Epilepsy
- 0.63
- Seizure
- 0.61
- Bilateral tonic-clonic seizure
- 0.60
- Botulism
- 0.58
- Neurodegenerative disease
- 0.55
- Developmental and epileptic encephalopathy 113
- 0.48
- Abnormality of the skeletal system
- 0.45
- Focal-onset seizure
- 0.41
- Fibromyalgia
- 0.37
- Focal impaired awareness seizure
- 0.37
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- SV2A
- Related
- Synaptic vesicle protein
Drugs and mechanisms are from ChEMBL CHEMBL1998 (CC BY-SA 3.0). Gene name, function (UniProt Q7L0J3, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets